Inhibition of Angiogenesis as a Treatment Strategy for Neuroblastoma (E-pub Ahead of Print)
Angiogenesis stands as a symbol for the development of tumor as well as its metastasis. In this review, we discuss the various components that induce and enhance angiogenesis along with its several inhibitors in neuroblastoma. Angiogenesis is vital for tumor development and migration and it is dependent on the creation of angiogenic elements by tumor cell lines. Neuroblastoma (NB) is a general pediatric tumor which originated from neural crest that is biologically and physiologically diverse. As tumor vascular index increases it leads to the unfavourable consequence of NB. Tumor vascularity is very much interrelated with an ill consequence of neuroblastoma. Hence, unique drugs which aim at the vascular endothelium are applicants for integration into clinical experimentation. As the quest for new anti-angiogenic compounds goes on, several angiogenic inhibitors get discovered whose progress needs to be scrutinized from time to time. Anti-angiogenic activity of a drug gets elevated when used as combination therapy than monotherapy. Vascular targeting is yet another strategy to increase the efficacy of anti-angiogenic therapy. In general for children having neuroblastoma the anti-angiogenic therapy works as a boon when administered along with gene therapy. As a resulting discovery of unique molecular objective and inhibition mediators has become the new attention of exploration for neuroblastoma researchers. The further discussion proceeds with understanding the process of angiogenesis, its clinical inferences, and future perspectives. Novel and more efficient methodologies are required to diagnose and treat extremely antagonistic neuroblastoma.
Keywords: Angiogenesis, Neuroblastoma, Anti-angiogenic, Tumor, Inhibition
Rights & PermissionsPrintExport